ANDA 215808, held by Fresenius Kabi USA. Ketamine Hydrochloride.
As of Nov 16, 2026, ANDA 215808 (Ketamine Hydrochloride), held by Fresenius Kabi USA, was first approved by FDA on Jan 13, 2023, with 0 approved supplements and 0 published complete response letters.
Ketamine Hydrochloride Injection is indicated: as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. for the induction of anesthesia prior to the administration of other general anesthetic agents. as a supplement to other anesthetic agents.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 13, 2023 | Original application | Approved | None posted |
| Ketamine HydrochlorideEQ 10MG BASE/ML · injectable;injection | Ketamine Hydrochloride | Rx |
| Ketamine HydrochlorideEQ 50MG BASE/ML · injectable;injection | Ketamine Hydrochloride | Rx |
| Ketamine HydrochlorideEQ 100MG BASE/ML · injectable;injection | Ketamine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters